Raja‐Khan 2011.

Study characteristics
Methods	Study design: randomized, double‐blind, placebo controlled Masking: double‐blind Number of arms: 2
Participants	Inclusion criteria: Women with PCOS and LDL‐cholesterol > 100 mg/dL were eligible to participate in the study. Exclusion criteria: not reported Baseline characteristics Placebo n: 11 sex: female age: 29.4 BMI: 36.0 Total cholesterol: 202.8 mg/dL (5.24 mmol/L) LDL cholesterol: 131.3 mg/dL (3.40 mmol/L) HDL cholesterol: 46.5 mg/dL (1.20 mmol/L) Triglycerides: 125.5 mg/dL (1.42 mmol/L) Total testosterone: 92.3 ng/dL (3.20 nmol/L) Free testosterone: 20.2 ng/dL (0.70 nmol/L) DHEAS: 170.2 μg/dL (4.62 μmol/L) Androstenedione: 380 ng/dL (13.27 nmol/L) 40 mg/day atorvastatin n: 9 sex: female age: 33.8 BMI: 40.1 Total cholesterol: 215.8 mg/dL (5.58 mmol/L) LDL cholesterol: 140.7 mg/dL (3.64 mmol/L) HDL cholesterol: 44.4 mg/dL (1.15 mmol/L) Triglycerides: 153.3 mg/dL (1.73 mmol/L) Total testosterone: 61.3 ng/dL (2.13 nmol/L) Free testosterone: 18.1 ng/dL (0.63 nmol/L) DHEAS: 162.9 μg/dL (4.42 μmol/L) Androstenedione: 340 ng/dL (11.87 nmol/L)
Interventions	Placebo for 6 weeks Atorvastatin 40 mg/day for 6 weeks
Outcomes	Total testosterone, Free testosterone, Androstenedione and DHEAS
Statistical analysis and reporting	Linear mixed‐effects models, extensions of regression that account for within‐subject correlation inherent in pre‐post designs, were fit to continuous outcomes to assess the change from baseline to 6weeks within and between treatment groups. All hypotheses tests were two‐sided. All analyses were performed by intention‐to‐treat using SAS software, version 9.1 (SAS Institute Inc., Cary, NC)
Number of participants lost to follow‐up	2
Source of funding	National Institutes of Health (NIH) grant number K12HD055882, GCRC grant M01 RR10732 and construction grant C06 RR016499 to Pennsylvania State University and a research grant from Pfizer
Notes	Location: Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania Ethical approval: The institutional review board of Pennsylvania State University approved the study. Written informed consent was obtained from all participants.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"The biostatistician generated a permuted block randomisation scheme"
Allocation concealment (selection bias)	Low risk	"The biostatistician generated a permuted block randomisation scheme for the allocation sequence and provided it to the pharmacist"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The atorvastatin and placebo were over encapsulated by the pharmacist so that the participants, research coordinator who administered the intervention, and investigators who assessed the outcomes were blinded to group assignment and objective outcome like serum androgens are not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Androgens were measured in a laboratory and the outcome measurements were not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias): WDAEs	Unclear risk	Not reported
Selective reporting (reporting bias)	Low risk	Study protocol is available (NCT00529542) and all the study's prespecified outcomes were reported
Selective reporting (reporting bias) WDAEs	High risk	Not reported
Source of funding, sponsorship and conflict of interest	High risk	National Institutes of Health (NIH) grant number K12HD055882, GCRC grant M01 RR10732 and construction grant C06 RR016499 to Pennsylvania State University and a research grant from Pfizer N.R‐K. has nothing to disclose. A.R.K. reports ownership of Merck stock. C.S.H. has nothing to disclose. C.M.S. has nothing to disclose. L.M.D. has nothing to disclose. R.S.L. has received speaker honorarium from Merck‐Serono and study support from Solvay
Incomplete outcome data (attrition bias): Total testosterone	Unclear risk	(20‐18)*100/20 = 10% did not complete the trial but the authors included all the data of all participants in the analysis
Incomplete outcome data (attrition bias): Free testosterone	High risk	Only baseline free testosterone was reported in each group
Incomplete outcome data (attrition bias): Androstenedione	Unclear risk	(20‐18)*100/20 = 10% did not complete the trial but the authors included all the data of all participants in the analysis
Incomplete outcome data (attrition bias): DHEAS	Unclear risk	(20‐18)*100/20 = 10% did not complete the trial but the authors included all the data of all participants in the analysis